{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:21:49Z","timestamp":1761060109575},"reference-count":74,"publisher":"AACN Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:p>Sepsis is associated with marked mortality, which may be reduced by prompt initiation of adequate, appropriate doses of antibiotic. Critically ill patients often have physiological changes that reduce blood and tissue concentrations of antibiotic and high rates of multidrug-resistant pathogens, which may affect patients\u2019 outcomes. All critical care professionals, including critical care nurses, should understand antibiotic pharmacokinetics and pharmacodynamics to ensure sound antibiotic dosing and administration strategies for optimal microbial killing and patients\u2019 outcomes. Effective pathogen eradication occurs when the dose of antibiotic reaches or maintains optimal concentrations relative to the minimum inhibitory concentration for the pathogen. Time-dependent antibiotics, such as \u03b2-lactams, can be given as extended or continuous infusions. Concentration-dependent antibiotics such as aminoglycosides are optimized by using high, once-daily dosing strategies with serum concentration monitoring. Vancomycin and fluoroquinolones are dependent on both time and concentration above the minimum inhibitory concentration.<\/jats:p>","DOI":"10.4037\/ccn2016881","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T18:32:49Z","timestamp":1459535569000},"page":"22-32","source":"Crossref","is-referenced-by-count":9,"title":["Application of Antibiotic Pharmacodynamics and Dosing Principles in Patients With Sepsis"],"prefix":"10.4037","volume":"36","author":[{"given":"Molly E.","family":"Droege","sequence":"first","affiliation":[{"name":"Molly E. Droege is a clinical pharmacy specialist, trauma, surgery, orthopedics, UC Health\u2013University of Cincinnati Medical Center, and an assistant professor of clinical pharmacy and an adjunct instructor of advanced clinical nursing University of Cincinnati, Cincinnati, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne L.","family":"Van Fleet","sequence":"additional","affiliation":[{"name":"Suzanne L. Van Fleet is a clinical pharmacy specialist, critical care, UC Health\u2013West Chester Hospital, West Chester, Ohio, and an assistant professor of clinical pharmacy and an adjunct instructor of advanced clinical nursing, University of Cincinnati."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric W.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Eric W. Mueller is an assistant director, clinical services and research, and a clinical pharmacy specialist, critical care, Department of Pharmacy Services, UC Health\u2013University of Cincinnati Medical Center. He is also an adjunct associate professor of pharmacy practice and an adjunct instructor of advanced clinical nursing, University of Cincinnati."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"issue":"1","key":"2019112612121756200_b1-0360022","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"International Surviving Sepsis Campaign Guidelines Committee. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 [published correction appears in Crit Care Med. 2008;36(4): 1394\u20131396]","volume":"36","author":"Dellinger","year":"2008","journal-title":"Crit Care Med"},{"key":"2019112612121756200_b2-0360022","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019112612121756200_b3-0360022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CCM.0b013e3181cb0cdc","article-title":"The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis","volume":"38","author":"Levy","year":"2010","journal-title":"Crit Care Med"},{"issue":"2","key":"2019112612121756200_b4-0360022","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Committee including the Pediatric Subgroup. Surviving Sepsis Campaign: international guideline for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"issue":"6","key":"2019112612121756200_b5-0360022","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"8","key":"2019112612121756200_b6-0360022","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00003088-200645080-00001","article-title":"Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis","volume":"45","author":"Roberts","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"2019112612121756200_b7-0360022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10156-003-0279-X","article-title":"Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling","volume":"9","author":"Nicolau","year":"2003","journal-title":"J Infect Chemother"},{"issue":"(6)(suppl 1)","key":"2019112612121756200_b8-0360022","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjmed.2006.04.001","article-title":"Pharmacodynamics: relation to antimicrobial resistance","volume":"119","author":"Rybak","year":"2006","journal-title":"Am J Med"},{"issue":"suppl 1","key":"2019112612121756200_b9-0360022","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/48.suppl_1.5","article-title":"Determination of minimum inhibitory concentrations","volume":"48","author":"Andrews","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2019112612121756200_b10-0360022","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/CCM.0b013e318180fe62","article-title":"Antibiotic resistance\u2014what\u2019s dosing got to do with it?","volume":"36","author":"Roberts","year":"2008","journal-title":"Crit Care Med"},{"key":"2019112612121756200_b11-0360022","first-page":"2377","volume-title":"United States Pharmacopeia of Dispensing Information","author":"Penicillins","year":"2006","edition":"26th ed"},{"issue":"suppl 2","key":"2019112612121756200_b12-0360022","first-page":"ii25","article-title":"Antibiotic dosing in critical illness","volume":"66","author":"McKenzie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2019112612121756200_b13-0360022","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2019112612121756200_b14-0360022","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1345\/aph.1M304","article-title":"Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin\/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients","volume":"43","author":"Shea","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2019112612121756200_b15-0360022","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbepenems and piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2019112612121756200_b16-0360022","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1128\/AAC.02759-14","article-title":"Extended-infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center","volume":"58","author":"Cutro","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019112612121756200_b17-0360022","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcrc.2014.07.033","article-title":"Prolonged vs intermittent infusion of piperacillin\/tazobactam in critically ill patients: a narrative and systemic review","volume":"29","author":"Yusuf","year":"2014","journal-title":"J Crit Care"},{"issue":"11","key":"2019112612121756200_b18-0360022","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1592\/phco.27.11.1490","article-title":"Optimal dosing of piperacillintazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?","volume":"27","author":"Kim","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2019112612121756200_b19-0360022","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1310\/hpj4905-444","article-title":"Administration of extended infusion piperacillin-tazobactam with the use of smart pump technology","volume":"49","author":"Maddox","year":"2014","journal-title":"Hosp Pharm"},{"issue":"1","key":"2019112612121756200_b20-0360022","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0149-2918(00)87978-3","article-title":"Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion","volume":"22","author":"Burgess","year":"2000","journal-title":"Clin Ther"},{"issue":"8","key":"2019112612121756200_b21-0360022","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1097\/01.CCM.0000069734.38738.C8","article-title":"Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia","volume":"31","author":"Boselli","year":"2003","journal-title":"Crit Care Med"},{"issue":"4","key":"2019112612121756200_b22-0360022","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.01141-08","article-title":"Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019112612121756200_b23-0360022","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1128\/AAC.01183-09","article-title":"Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2019112612121756200_b24-0360022","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit Care"},{"key":"2019112612121756200_b25-0360022","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.43.10.2559","article-title":"Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing","volume":"43","author":"Lipman","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2019112612121756200_b26-0360022","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1592\/phco.23.3.291.32110","article-title":"Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa","volume":"23","author":"Tam","year":"2003","journal-title":"Pharmacotherapy"},{"key":"2019112612121756200_b27-0360022","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduced mortality in patients with Pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agent Chemother"},{"issue":"5","key":"2019112612121756200_b28-0360022","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200544050-00007","article-title":"Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis","volume":"44","author":"Novelli","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2019112612121756200_b29-0360022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1345\/aph.1M339","article-title":"Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review","volume":"44","author":"Perrot","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2019112612121756200_b30-0360022","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1128\/AAC.49.4.1337-1339.2005","article-title":"Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection","volume":"49","author":"Jaruratanasirikul","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2019112612121756200_b31-0360022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2019112612121756200_b32-0360022","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.49.5.1881-1889.2005","article-title":"Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers","volume":"49","author":"Krueger","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2019112612121756200_b33-0360022","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"issue":"2","key":"2019112612121756200_b34-0360022","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1345\/aph.1R523","article-title":"Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study","volume":"47","author":"Arnold","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2019112612121756200_b35-0360022","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1345\/aph.1M462","article-title":"Comparative pharmacodynamics of intermittent and prolonged infusion of piperacillin\/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients","volume":"43","author":"Rotschafer","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2019112612121756200_b36-0360022","unstructured":"ASHP\u2019s interactive handbook on injectable drugs. http:\/\/www.interactivehandbook.com. Accessed June 24, 2013."},{"issue":"3","key":"2019112612121756200_b37-0360022","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-200140030-00003","article-title":"Comparative pharmacokinetics and pharmacodynamics of newer fluoroquinolone antibacterials","volume":"40","author":"Aminimanizani","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2019112612121756200_b38-0360022","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.idc.2009.06.003","article-title":"The newer fluoroquinolones","volume":"23","author":"Bolon","year":"2009","journal-title":"Infect Dis Clin North Am"},{"issue":"8","key":"2019112612121756200_b39-0360022","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/0091270009355160","article-title":"Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections","volume":"50","author":"Zhang","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2019112612121756200_b40-0360022","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/00003088-200544060-00004","article-title":"Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients","volume":"44","author":"S\u00e1nchez Navarro","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2019112612121756200_b41-0360022","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1128\/AAC.00566-10","article-title":"Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease","volume":"55","author":"Kontou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2019112612121756200_b42-0360022","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"2019112612121756200_b43-0360022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ccc.2010.11.005","article-title":"Optimal use of fluoroquinolones in the intensive care unit setting","volume":"27","author":"Rotschafer","year":"2011","journal-title":"Crit Care Clin"},{"issue":"8","key":"2019112612121756200_b44-0360022","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/jac\/dkr220","article-title":"Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulation","volume":"66","author":"Khachman","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2019112612121756200_b45-0360022","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-2007-996406","article-title":"Optimizing use of aminoglycosides in the critically ill","volume":"28","author":"Rea","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"issue":"23","key":"2019112612121756200_b46-0360022","first-page":"e394","article-title":"Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America","volume":"111","author":"Baddour","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"2019112612121756200_b47-0360022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/514620","article-title":"The pharmacodynamics of aminoglycosides","volume":"27","author":"Lacy","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2019112612121756200_b48-0360022","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/162.2.408","article-title":"The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing","volume":"162","author":"Jackson","year":"1990","journal-title":"J Infect Dis"},{"issue":"4","key":"2019112612121756200_b49-0360022","first-page":"319","article-title":"Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides","volume":"5","author":"Deziel-Evans","year":"1986","journal-title":"Clin Pharm"},{"issue":"2","key":"2019112612121756200_b50-0360022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J Infect Dis"},{"issue":"3","key":"2019112612121756200_b51-0360022","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2019112612121756200_b52-0360022","first-page":"227","article-title":"Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review","volume":"6","author":"Velissaris","year":"2014","journal-title":"J Clin Med Res"},{"issue":"1","key":"2019112612121756200_b53-0360022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1128\/AAC.41.1.49","article-title":"Once-daily gentamicin therapy for experimental Escherichia coli meningitis","volume":"41","author":"Ahmed","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2019112612121756200_b54-0360022","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1378\/chest.128.2.545","article-title":"Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia","volume":"128","author":"Panidis","year":"2005","journal-title":"Chest"},{"key":"2019112612121756200_b55-0360022","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/QCO.0000000000000012","article-title":"Aminoglycosides: how should we use them in the 21st century?","volume":"26","author":"Jackson","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"6","key":"2019112612121756200_b56-0360022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/39.6.677","article-title":"Once-daily dosing of aminoglycosides: review and recommendations for clinical practice","volume":"39","author":"Freeman","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2019112612121756200_b57-0360022","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2019112612121756200_b58-0360022","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1097\/01.CCM.0000134832.11144.CB","article-title":"Effect of once-daily dosing vs multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity","volume":"32","author":"Olsen","year":"2004","journal-title":"Crit Care Med"},{"key":"2019112612121756200_b59-0360022","first-page":"95","volume-title":"United States Pharmacopeia of Dispensing Information","author":"Aminoglycosides","year":"2006","edition":"26th ed"},{"key":"2019112612121756200_b60-0360022","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-2007-996406","article-title":"Optimizing use of aminoglycosides in the critically ill","volume":"28","author":"Rea","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"2019112612121756200_b61-0360022","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.idc.2009.06.010","article-title":"Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinipristin\/dalfopristin, oxazolidinedinones, daptomycin, dalbavancin, and telavancin","volume":"23","author":"Nailor","year":"2009","journal-title":"Infect Dis Clin North Am"},{"key":"2019112612121756200_b62-0360022","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/AAC.42.10.2739","article-title":"In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis","volume":"42","author":"Lowdin","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"2019112612121756200_b63-0360022","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2019112612121756200_b64-0360022","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists [published correction appears in Am J Health Syst Pharm. 2009;66(10):887]","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"suppl 1","key":"2019112612121756200_b65-0360022","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019112612121756200_b66-0360022","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jcpt.12200","article-title":"Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review","volume":"39","author":"Polso","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2019112612121756200_b67-0360022","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0897190014546114","article-title":"Vancomycin nephrotoxicity: a review","volume":"27","author":"Mergenhagen","year":"2014","journal-title":"J Pharm Pract"},{"issue":"4","key":"2019112612121756200_b68-0360022","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2019112612121756200_b69-0360022","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1097\/CCM.0000000000000514","article-title":"Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis","volume":"42","author":"Hanrahan","year":"2014","journal-title":"Crit Care Med"},{"issue":"7","key":"2019112612121756200_b70-0360022","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors","volume":"34","author":"Meaney","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2019112612121756200_b71-0360022","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"7","key":"2019112612121756200_b72-0360022","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime","volume":"34","author":"Gomes","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2019112612121756200_b73-0360022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ccc.2010.09.006","article-title":"Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock","volume":"27","author":"Varghese","year":"2011","journal-title":"Crit Care Clin"},{"issue":"9","key":"2019112612121756200_b74-0360022","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1086\/513203","article-title":"The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus","volume":"44","author":"Tenover","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Critical Care Nurse"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/36\/2\/22\/121074\/22.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/36\/2\/22\/121074\/22.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T17:45:42Z","timestamp":1574790342000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/ccnonline\/article\/36\/2\/22\/3632\/Application-of-Antibiotic-Pharmacodynamics-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.4037\/ccn2016881","relation":{},"ISSN":["0279-5442","1940-8250"],"issn-type":[{"value":"0279-5442","type":"print"},{"value":"1940-8250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,1]]}}}